

Ballard Spahr, LLP
100 N. City Parkway, Suite 1750
Las Vegas, Nevada 89106

1 Stanley W. Parry, Esq.
Nevada Bar No. 1417
2 BALLARD SPAHR LLP
100 North City Parkway
3 Suite 1750
4 Las Vegas, NV 89106-4617
Telephone: (702) 471-7000
5 Facsimile: (702) 471-7070
Email: parrys@ballardspahr.com
6

7 Charles E. Lipsey, Esq.
FINNEGAN, HENDERSON, FARABOW,
8 GARRETT & DUNNER, L.L.P.
Two Freedom Square
9 11955 Freedom Drive
Reston, Virginia 20190
10 (571) 203-2700

11 Laura P. Masurovsky, Esq.
12 Mark J. Feldstein, Esq.
FINNEGAN, HENDERSON, FARABOW,
13 GARRETT & DUNNER, L.L.P.
901 New York Avenue, N.W.
14 Washington, D.C. 20001-4413
15 (202) 408-4000

16 (Pro Hac Vice Applications Pending)

17 Attorneys for Plaintiff
18 ELI LILLY AND COMPANY

19 **UNITED STATES DISTRICT COURT**
20 **DISTRICT OF NEVADA**

22 **ELI LILLY AND COMPANY**
23 Plaintiff,
24
25 v.
26 **WATSON PHARMACEUTICALS, INC.,**
WATSON LABORATORIES, INC. and
27 **WATSON PHARMA, INC.,**
28 Defendants.

CIVIL ACTION NO. 2:10-CV-00647
**NOTICE OF VOLUNTARY
DISMISSAL WITHOUT PREJUDICE**

1 Pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), Plaintiff Eli Lilly and Company
2 (“Lilly”), by and through their counsel, file this voluntary dismissal without prejudice. On July 21,
3 2010, Lilly and defendants Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., and Watson
4 Pharma, Inc. (collectively “Defendants”) filed a joint motion in *Eli Lilly and Company v. Watson*
5 *Pharmaceuticals, Inc., et al.*, Civil Action No. 1:10-cv-00549-SEB-WGH (S.D. Ind. filed May 3,
6 2010) , wherein Defendants agreed that they shall not contest jurisdiction or venue in that action.
7 (See Ex. 1 (D.I. 13), ¶5.) The motion was granted on July 22, 2010. (See Ex. 2 (D.I. 14).) In view
8 thereof, Lilly hereby gives notice that the above-captioned action is voluntarily dismissed, without
9 prejudice, against the Defendants.

10
11 Respectfully submitted this 6th day of August, 2010.

Ballard Spahr, LLP
100 N. City Parkway, Suite 1750
Las Vegas, Nevada 89106

12
13
14
15 /s/ Stanley W. Parry
16 Stanley W. Parry, Esq.
17 Nevada Bar No. 1417
18 BALLARD SPAHR LLP
19 100 North City Parkway
20 Suite 1750
21 Las Vegas, NV 89106-4617
22 Telephone: (702) 471-7000
23 Email: bundickj@ballardspahr.com

24 Attorney for Plaintiff
25 ELI LILLY AND COMPANY

26 Charles E. Lipsey
27 FINNEGAN, HENDERSON, FARABOW,
28 GARRETT & DUNNER, L.L.P.
Two Freedom Square
11955 Freedom Drive
Reston, Virginia 20190
(571) 203-2700

Ballard Spahr, LLP
100 N. City Parkway, Suite 1750
Las Vegas, Nevada 89106

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Laura P. Masurovsky
Mark J. Feldstein
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413
(202) 408-4000

It is SO ORDERED.

DATED: 12 Aug, 2010


UNITED STATES DISTRICT JUDGE

EXHIBIT 1

EXHIBIT 1

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION

ELI LILLY AND COMPANY,)	
)	
Plaintiff,)	
)	
v.)	CASE NO. 1:10-cv-0549 SEB-WGH
)	
WATSON PHARMACEUTICALS, INC.,)	
WATSON LABORATORIES, INC., AND)	
WATSON PHARMA, INC.,)	
)	
Defendants.)	

**AGREED MOTION TO STAY PROCEEDINGS PENDING FEDERAL CIRCUIT'S
RULING IN *ELI LILLY AND COMPANY v. TEVA PHARMACEUTICALS, INC.***

Plaintiff Eli Lilly and Company (“Lilly”), by counsel, and Defendants Watson Pharmaceuticals, Inc., Watson Laboratories, Inc. and Watson Pharma, Inc. (“Watson”), by counsel, hereby request the Court enter an order staying these proceedings pending a decision by the Court of Appeals for the Federal Circuit (“Federal Circuit”) in *Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.*, Case No. 1:06-cv-1017-SEB-JMS (the “Lilly/Teva Action”) regarding the validity of U.S. Patent Nos. 6,458,811, 6,797,719, and/or 6,894,064 owned by Lilly (“the Lilly patents”). In support of such request, the parties state:

1. On May 3, 2010, Lilly filed its Complaint for patent infringement against Watson in which it alleges that Watson’s filing of Abbreviated New Drug Application No. 200825 infringes the Lilly patents, all of which are listed within FDA’s Publication entitled “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the “Orange Book”) in connection with Lilly’s EVISTA® (Raloxifene Hydrochloride) product.

2. In the Lilly/Teva Action, on September 23, 2009, this Court entered its Findings of Fact and Conclusions of Law following a bench trial (“September 23, 2009 Findings”) in

which it, in part, held that certain claims in the Lilly patents were invalid for lack of written description. The Lilly patents at issue in the Lilly/Teva Action are the same patents at issue in this case.

3. Cross-appeals of the September 23, 2009 Findings, including Lilly's appeal of this Court's determination that the Lilly patents are invalid, are fully briefed and oral argument before the Federal Circuit panel occurred on June 7, 2010.

4. The parties agree that due to the overlapping issues in this case and in the Lilly/Teva Action, in the interest of judicial economy and efficiency, these proceedings should be stayed pending a decision by the Federal Circuit in the Lilly/Teva Action as to the validity of one or more of the Lilly patents.

5. Watson disputes that jurisdiction and venue for the claims within Lilly's Complaint are proper in the United States District Court for the Southern District of Indiana, but Watson hereby agrees that it shall not contest jurisdiction or venue in this action.

WHEREFORE, the parties request the Court enter an order staying these proceedings pending a decision by the Federal Circuit as to the validity of one or more of the Lilly patents or upon written request to the Court by either party, and for all other proper relief.

Respectfully submitted,

s/ Michael Rabinowitch
 Michael Rabinowitch, #18117-49
 WOODEN & MCLAUGHLIN LLP
 One Indiana Square, Suite 1800
 Indianapolis, IN 46204-4208

**Attorney for Defendants
 Watson Pharmaceuticals, Inc.,
 Watson Laboratories, Inc. and
 Watson Pharma, Inc.**

s/ Jan M. Carroll¹
 Jan M. Carroll, #4187-49
 BARNES & THORNBURG LLP
 11 S. Meridian Street
 Indianapolis, IN 46204

**Attorney for Plaintiff
 Eli Lilly and Company**

¹ Signed by Michael Rabinowitch pursuant to authority and with consent of counsel.

EXHIBIT 2

EXHIBIT 2

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION

ELI LILLY AND COMPANY,)	
)	
Plaintiff,)	
)	
v.)	CASE NO. 1:10-cv-0549 SEB-WGH
)	
WATSON PHARMACEUTICALS, INC.,)	
WATSON LABORATORIES, INC., AND)	
WATSON PHARMA, INC.,)	
)	
Defendants.)	


ORDER GRANTING AGREED MOTION TO STAY PROCEEDINGS

This matter is before the Court on the parties' Agreed Motion to Stay Proceedings Pending Federal Circuit's Ruling in *Eli Lilly and Company v. Teva Pharmaceuticals, Inc.*.

The Court, after having considered the matter and being otherwise duly advised, now finds that the Motion should be granted.

IT IS THEREFORE ORDERED, ADJUDGED AND DECREED that these proceedings are stayed pending a decision by the United States Court of Appeals for the Federal Circuit in *Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.*, Case No. 1:06-cv-1017-SEB-JMS (the "Lilly/Teva Action") regarding the validity of one or more of U.S. Patent Nos. 6,458,811, 6,797,719, and/or 6,894,064 owned by Lilly or upon written request to the Court by either party.

Dated this 22nd day of July, 2010.


WILLIAM G. HUSSMANN, JR.
Magistrate Judge

Distribution:

Michael Rabinowitch
WOODEN & MCLAUGHLIN LLP
211 N. Pennsylvania
One Indiana Square, Suite 1800
Indianapolis, IN 46204-4208

Jan M. Carroll
BARNES & THORNBURG LLP
11 S. Meridian Street
Indianapolis, IN 46204